Holen Sie sich die Stockscreener-App
1.40
6.04%
-0.09
Handel nachbörslich:
1.40
Schlusskurs vom Vortag:
$1.49
Offen:
$1.49
24-Stunden-Volumen:
798.32K
Relative Volume:
0.36
Marktkapitalisierung:
$178.73M
Einnahmen:
$79.18M
Nettoeinkommen (Verlust:
$-136.99M
KGV:
-1.3274
EPS:
-1.0547
Netto-Cashflow:
$-120.11M
1W Leistung:
-19.08%
1M Leistung:
+33.33%
6M Leistung:
-68.04%
1J Leistung:
-66.10%
1-Tages-Spanne:
$1.40
$1.51
1-Wochen-Bereich:
$1.40
$1.87
52-Wochen-Spanne:
$0.7796
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Compare ADCT vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.40 | 178.73M | 79.18M | -136.99M | -120.11M | -1.0547 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-06-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull Thesis - Seeking Alpha
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements - PR Newswire
Adc Therapeutics Sa (ADCT-N) Stock Price and News - The Globe and Mail
ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Receives Average Recommendation of "Hold" from Brokerages - marketbeat.com
ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow - Seeking Alpha
ADC Therapeutics at Cantor conference: zynlonta growth plan faces FDA test - Investing.com Nigeria
ADCT: ZYNLONTA shows high response rates and regulatory momentum in DLBCL and lymphoma studies - TradingView
ADCT: Promising LOTIS-7 results and robust cash position support expansion in lymphoma markets - TradingView
ADC Therapeutics at Cantor conference: zynlonta growth plan faces FDA test - Investing.com India
ADC Therapeutics at Cantor conference: zynlonta growth plan faces FDA test - Investing.com UK
ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.9%Time to Sell? - marketbeat.com
ADC Therapeutics SA (ADCT) Stock Price & News - Syfe
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - morningstar.com
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - PR Newswire
ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses - Yahoo Finance
ADC Therapeutics SA (ADCT) Stock News Today - TradingKey
ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript - AOL.com
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Following a 56% Decline Over Last Year, Recent Gains May Please ADC Therapeutics SA (NYSE:ADCT) Institutional Owners - 富途牛牛
Guggenheim cuts ADC Therapeutics stock price target on FDA concerns By Investing.com - Investing.com South Africa
Guggenheim cuts ADC Therapeutics stock price target on FDA concerns By Investing.com - Investing.com UK
Antibody-Drug Conjugates (ADC) Market Set to Witness Significant - The National Law Review
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook - Yahoo Finance
ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen - MarketBeat
Nantahala group discloses 9.69% ADC Therapeutics (ADCT) ownership in 13G filing - Stock Titan
ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says - marketscreener.com
ADC Therapeutics S.A. Q2 2026 Earnings Call Summary - Yahoo Finance
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... - Yahoo! Finance Canada
ADC Therapeutics Q2 Earnings Call Highlights - MarketBeat
ADC Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968 - marketscreener.com
ADC Therapeutics Q2 Results: Net Loss Falls 71% to $16.6 Million - scanx.trade
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Nigeria
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Australia
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com South Africa
ADC Therapeutics SA reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com India
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Canada
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com UK
ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings call transcript: ADC Therapeutics beats Q2 2026 estimates but shares fall - Investing.com
ADC Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings - Moomoo
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings | ADCT Stock News - Quiver Quantitative
ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss - TradingKey
ADC Therapeutics SA (ADCT) Latest Stock News & Headlines - Yahoo Finance
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates - Yahoo Finance
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adc Therapeutics Sa-Aktie (ADCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 10% Owner |
Apr 02 '26 |
Sale |
3.28 |
2,529,491 |
8,294,201 |
10,265,297 |
| Redmile Group, LLC | 10% Owner |
Apr 01 '26 |
Sale |
3.80 |
169,265 |
643,038 |
15,301,237 |
| Redmile Group, LLC | 10% Owner |
Apr 01 '26 |
Sale |
3.80 |
162,517 |
617,402 |
12,794,788 |
| Redmile Group, LLC | 10% Owner |
Mar 31 '26 |
Sale |
3.75 |
196,229 |
736,251 |
15,470,502 |
| Redmile Group, LLC | 10% Owner |
Mar 31 '26 |
Sale |
3.75 |
188,407 |
706,903 |
12,957,305 |
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):